BioPartners Holdings AG

BioPartners, established in 2000, aims to become a leader in the development and commercialization of innovative formulations and novel delivery systems for first-generation biopharmaceuticals, where there is a significant unmet patient/medical need. BioPartners is committed to providing safe, effective, and competitively priced biopharmaceutical therapies. Its portfolio covers the fields of endocrinology, multiple sclerosis, and virology.Headquartered in Switzerland and part of Germany, BioPartners is building an international network through a series of collaborations and partnerships with leading development and service partners. BioPartners is currently negotiating commercial agreements for product distribution in all relevant markets with major companies.BioPartners is owned by Bioton SA, a dynamically growing Polish biotechnology company that produces clinically important drugs such as recombinant human insulin.